Fully cell-free process aims to further democratize personalized cancer therapeutic manufacturing with shorter turnaround times and negligible bioburden and endotoxin risks. As late-stage PCT clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback